ReviewArchives of microbiology2026
Cordyceps as a multitarget therapeutic platform: biology, bioactive metabolites, and translational challenges.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cordyceps-related fungi have garnered global attention as multifunctional therapeutic resources owing to their exclusive entomopathogenic biology, remarkable metabolic diversity, and expanding pharmaceutical bearing. Recent taxonomic revisions determined by molecular phylogenetics have redefined the traditional notion of Cordyceps, revealing distinct evolutionary lineages with species-specific metabolite profiles and biological functions. This review provides a complete and evidence-based synthesis of the taxonomy, ecology, host interactions, chemical composition, biosynthetic pathways, pharmacological activities, and translational prospects of chief medicinal species, including Ophiocordyceps sinensis, Cordyceps militaris, Cordyceps cicadae, and related taxa. Particular emphasis is placed on cordycepin, the signature bioactive nucleoside, and its integration with broader metabolite networks encompassing polysaccharides, sterols, peptides, and secondary metabolites. Current evidence demonstrates that Cordyceps-derived compounds influence multiple interconnected signaling pathways, including AMPK, PI3K/Akt/mTOR, NF-κB, MAPK, and oxidative stress-response networks, thereby contributing to immunomodulatory, anti-inflammatory, antimicrobial, anticancer, neuroprotective, and metabolic regulatory effects. The review further reviews recent advances in genomics, transcriptomics, metabolomics, biosynthetic gene-cluster analysis, synthetic biology, metabolic engineering, and exactness fermentation technologies that are redesigning Cordyceps research and industrial production. Critical challenges including species authentication, chemical standardization, pharmacokinetic limitations, product reproducibility, safety evaluation, regulatory requirements, and inadequate clinical validation are also discussed. By integrating biological identity, metabolite biosynthesis, molecular mechanisms, and technological innovation within a translational framework, this review positions Cordyceps as a promising systems-level platform for future therapeutics, functional foods, and precision mycotherapy.
Indexed as
Identifiers
42909627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.